Nanobiotix S.A. (NBTX)
NASDAQ: NBTX · IEX Real-Time Price · USD
5.40
-0.23 (-4.09%)
At close: Jul 19, 2024, 4:00 PM
5.28
-0.12 (-2.22%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Nanobiotix Employees
Nanobiotix had 102 employees as of December 31, 2023. The number of employees did not change compared to the previous year.
Employees
102
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$394,412
Profits / Employee
-$432,462
Market Cap
254.40M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 102 | 0 | - |
Dec 31, 2022 | 102 | 2 | 2.00% |
Dec 31, 2021 | 100 | 12 | 13.64% |
Dec 31, 2020 | 88 | -22 | -20.00% |
Dec 31, 2019 | 110 | 8 | 7.84% |
Dec 31, 2018 | 102 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
MultiPlan | 2,800 |
AirSculpt Technologies | 381 |
AVITA Medical | 207 |
Codexis | 174 |
Nektar Therapeutics | 137 |
Profound Medical | 131 |
Sanara MedTech | 108 |
CorMedix | 83 |
NBTX News
- 5 weeks ago - NANOBIOTIX to Host Virtual KOL Event Discussing Potential of NBTXR3 Combined With Immunotherapy in Head and Neck Cancer and Beyond on June 18, 2024 - GlobeNewsWire
- 7 weeks ago - Nanobiotix Announces New Data Showing Disease Control and Tumor Response in Patients Treated With RT-Activated NBTXR3 Followed By anti-PD-1 For 2l+ R/M HNSCC Naïve or Resistant to Prior anti-PD-1 Therapy - GlobeNewsWire
- 7 weeks ago - NANOBIOTIX Announces Presentation of new Data From Phase 1 Immunotherapy Program at the 2024 Annual Meeting of the American Society for Clinical Oncology Followed by an Investor Conference Call - GlobeNewsWire
- 2 months ago - NANOBIOTIX to Present at the Jefferies Global Healthcare Conference - GlobeNewsWire
- 2 months ago - NANOBIOTIX Provides First Quarter 2024 Operational and Financial Update - GlobeNewsWire
- 2 months ago - Nanobiotix Announces Progress in Global NBTXR3 Development Collaboration Highlighting Robust Pipeline and Pathway to Long-Term Growth - GlobeNewsWire
- 2 months ago - NANOBIOTIX to Announce First Quarter Operational and Financial Update on May 22, 2024 - GlobeNewsWire
- 2 months ago - NANOBIOTIX Announces US FDA Protocol Acceptance for New Randomized Phase 2 Study Evaluating NBTXR3 for Patients with Stage Three Lung Cancer - GlobeNewsWire